AOD-9604 HGH Fragment 176-191 Fat Loss Peptide

Fat Loss - HGH Fragment - Metabolic Health

Buy AOD-9604 Wholesale NYC

HGH Fragment 176-191 | Per Vial

From $35.00 / vial

4.8 / 5.0 - 263 reviews

AOD-9604 2mg VialPrice per vial

$35.00

AOD-9604 5mg VialPrice per vial

$63.00

AOD-9604 5-Vial Pack (2mg each)Bundle savings per pack

$157.00

Your Selection

Order Total$0.00

The targeted fat loss peptide: isolates the lipolytic region of growth hormone to burn fat without the insulin resistance, water retention, or IGF-1 elevation of full HGH

AOD-9604 is a modified fragment of the C-terminus of human growth hormone (amino acids 176-191). It was developed by Monash University in Australia and isolated specifically for its fat-burning properties. Unlike full HGH, AOD-9604 does not bind to the GH receptor and therefore does not stimulate IGF-1 production, cause insulin resistance, or produce the hyperglycemic effects of HGH. It mimics the way natural growth hormone regulates fat metabolism: stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (new fat formation), with a particularly strong effect on abdominal and visceral fat.

Targets fat metabolism directly - stimulates lipolysis and inhibits lipogenesis without IGF-1 elevation
Does not cause insulin resistance or hyperglycemia - safe metabolic profile compared to full HGH
Completed multiple Phase II clinical trials for obesity treatment - strong safety data in human subjects

Delivery

Fast Tracked Priority

Sourcing

USA Genuine Products

Support

Friendly Customer Care

Back to Peptides

The Fat-Loss Fragment: HGH Without the Side Effects

AOD-9604 was designed to deliver the fat-burning benefits of growth hormone without the well-documented downsides of full HGH therapy - insulin resistance, hyperglycemia, joint pain, and IGF-1-driven tissue growth. By isolating and modifying only the C-terminal fragment (amino acids 176-191) responsible for GH's lipolytic activity, researchers created a compound with a cleaner metabolic profile. AOD-9604 does not bind to the GH receptor and does not stimulate IGF-1, making it metabolically inert outside of its direct effects on adipose tissue.

Phase I and Phase II clinical trials conducted by Metabolic Pharmaceuticals demonstrated a favorable safety profile and statistically significant reductions in body weight compared to placebo in obese subjects. The compound progressed to a Phase IIb trial before development was discontinued for commercial rather than safety reasons.

Key Benefits

01Directly stimulates lipolysis in adipocytes - particularly effective on visceral and abdominal fat depots
02Inhibits lipogenesis - actively prevents new fat formation, not just promotes breakdown
03No IGF-1 elevation, no insulin resistance - a metabolically safe alternative to full HGH for fat loss protocols
04Completed human Phase II clinical trials with a well-characterized safety profile
05No effect on blood glucose - suitable for metabolically compromised individuals in supervised protocols

Product Specifications

Peptide Name	AOD-9604 (HGH Fragment 176-191)
Sequence	Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (cyclic)
Molecular Weight	1817.1 g/mol
Form	Lyophilized powder for reconstitution
Purity	> 99% (HPLC verified)
Storage	Refrigerate at 2-8C; protect from light
Price	From $35.00 per vial

Results Timeline

Weeks 1-2

Initial lipolytic activity begins. Users may notice mild thermogenic effect and early changes in body composition, particularly in the abdominal region.

Weeks 4-8

Measurable reductions in fat mass with consistent use alongside a caloric deficit. Protocol works synergistically with resistance training and controlled nutrition.

Extended Protocol

Best results observed in 12-16 week protocols. AOD-9604 pairs well with other metabolic peptides such as CJC-1295 and Ipamorelin for comprehensive GH optimization.

Step 1: Subcutaneous Administration

AOD-9604 is administered via subcutaneous injection, typically in the abdominal region or near target fat depots. It is rapidly absorbed and distributed systemically, reaching adipose tissue within 30-60 minutes of administration.

Step 2: Beta-3 Adrenergic Receptor Activation

AOD-9604 acts on adipocytes through beta-3 adrenergic receptor activation, triggering the same intracellular signaling cascade as endogenous GH's fat-metabolizing activity. This activates hormone-sensitive lipase (HSL) and promotes the release of free fatty acids from adipocytes into circulation for energy use.

Step 3: Lipolysis + Lipogenesis Inhibition

Unlike many weight loss compounds that only stimulate fat breakdown, AOD-9604 simultaneously inhibits lipogenesis - the metabolic pathway responsible for converting excess calories into stored fat. This dual action creates a favorable metabolic environment for net fat mass reduction even in the absence of severe caloric restriction.

Step 4: No Systemic Hormonal Disruption

Because AOD-9604 does not bind to the GH receptor (GHR), it does not trigger the IGF-1 axis and produces no measurable effect on insulin sensitivity, blood glucose, or thyroid hormones. This makes it distinctly advantageous compared to full HGH, which at equivalent fat-loss doses would cause significant metabolic disruption and organ enlargement risk.

Who Benefits Most from AOD-9604?

AOD-9604 is well-suited for adults seeking targeted fat loss - particularly visceral and abdominal fat - as part of a medically supervised body composition protocol. Its clean metabolic profile makes it appropriate for individuals who cannot use full HGH due to metabolic contraindications, and it pairs effectively with other peptides in a GH optimization stack.

Ideal Candidates

+Adults targeting stubborn abdominal or visceral fat resistant to diet and exercise alone
+Those seeking HGH-like fat loss benefits without the metabolic risks of full GH therapy
+Individuals on metabolic wellness or longevity protocols pairing peptides (e.g., CJC-1295 + Ipamorelin)
+Athletes and fitness-focused individuals maintaining muscle while reducing fat mass

Contraindications

-Pregnant or breastfeeding individuals
-Active malignancy - GH-related peptides should be avoided during cancer treatment without specialist guidance
-Children and adolescents - not for use in individuals under 18

Consult a licensed healthcare provider before beginning any peptide protocol. See Important Safety Information below.

AOD-9604 is a fragment of the HGH molecule (amino acids 176-191) that retains only the fat-metabolizing function of GH. Unlike full HGH, it does not bind to the GH receptor, does not elevate IGF-1, and does not affect insulin sensitivity or blood glucose. This means you get targeted fat loss without the bone/organ growth, water retention, joint pain, and metabolic disruption associated with full HGH therapy.

Most users begin to notice changes in body composition within 4-8 weeks of consistent use alongside a moderate caloric deficit. The most significant results are typically observed in 12-16 week protocols. AOD-9604 is not a rapid fat-loss agent - it works best as part of a sustained, medically supervised body recomposition protocol.

Yes. AOD-9604 is commonly used alongside GH secretagogues like CJC-1295 and Ipamorelin for comprehensive GH optimization. The combination aims to naturally elevate GH pulse amplitude (via CJC-1295/Ipamorelin) while using AOD-9604 to specifically target fat metabolism. This stack is among the most popular in anti-aging and body composition peptide protocols.

AOD-9604 is not FDA-approved as a pharmaceutical drug. It completed Phase I and Phase II clinical trials for obesity treatment in Australia and the US with favorable safety data, but development was halted for commercial reasons before Phase III. It holds FDA GRAS (Generally Recognized As Safe) status as a food ingredient (AOD9604). It is available as a research peptide for supervised wellness use.